In the pharmaceutical industry, Harrow justifies a 486% price increase for an injectable eye treatment due to the need for investment in supply restoration and perceived underpricing. Novartis plans to cut up to 680 jobs in product development, with 440 in Switzerland and up to 240 in the U.S., separate from a larger restructuring program. The company also plans to add roles, resulting in a 1%-2% net reduction in the global workforce. The success of the eye treatment relaunch and job cuts are dependent on reactions from specialists and the market. Subscribe for more exclusive content and updates.
Source link
We’re reading about a 486% drug price hike, AstraZeneca CEO pay
